Can hepatic steatosis (fatty liver) cause markedly elevated aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase with normal bilirubin and no other findings on computed tomography?

Fatty Liver Alone Does NOT Explain These Markedly Elevated Transaminases

While fatty liver disease can cause elevated liver enzymes, the degree of elevation you describe (AST 255, ALT 442, ALP 270) is atypically high for simple steatosis and demands investigation for other concurrent liver pathology, particularly nonalcoholic steatohepatitis (NASH), drug-induced liver injury, or other superimposed conditions.

Understanding the Enzyme Pattern

Your enzyme pattern shows:

• ALT 442 U/L (~10-13x upper limit of normal)
• AST 255 U/L (~6-8x upper limit of normal)
• ALP 270 U/L (~2-3x upper limit of normal)
• Normal bilirubin
• AST:ALT ratio <1 (255/442 = 0.58)

This represents a moderate-to-severe hepatocellular injury pattern with a mixed cholestatic component 1.

Why Simple Steatosis Is Unlikely

According to current guidelines, patients with nonalcoholic fatty liver disease (NAFLD) typically present with:

• ALT levels usually <250 IU/L (typically <5x upper limit of normal)
• Normal or mildly elevated enzymes in 70-75% of cases with simple steatosis
• ALT levels >300 U/L occur rarely in NAFLD 2

Your transaminases fall into the moderate elevation category (5-10x upper limit of normal), which suggests active hepatocyte injury beyond simple fat accumulation 1.

Most Likely Explanation: NASH with Active Inflammation

The enzyme elevations you describe are most consistent with nonalcoholic steatohepatitis (NASH) rather than simple steatosis 1. Here's why:

• NASH occurs in 25-30% of NAFLD patients and involves hepatocyte injury and inflammation due to lipid accumulation
• The ALT-predominant pattern (ALT > AST) with AST:ALT ratio <1 strongly suggests metabolic disease-related fatty liver rather than alcohol-induced disease 1
• The elevated alkaline phosphatase (270 U/L) can occur in NAFLD/NASH, though mild elevations (usually <2x ULN) are typical 2

Importantly, a subset of NAFLD patients present with isolated or disproportionate alkaline phosphatase elevation, particularly older females, and these patients may have more advanced disease including steatohepatitis 3.

Critical Caveat: CT Has Limited Sensitivity

CT scan showing only "fatty steatosis" does NOT exclude significant inflammation, fibrosis, or even cirrhosis 1. Imaging cannot reliably distinguish:

• Simple steatosis from NASH
• Degree of inflammation
• Presence of fibrosis or early cirrhosis

The fact that CT shows steatosis confirms fat accumulation but provides no information about the active hepatocyte injury that your elevated enzymes clearly indicate.

What Else Must Be Excluded

Given these markedly elevated transaminases, you must systematically exclude other causes of hepatocellular injury 1:

Essential workup includes:

• Viral hepatitis: Hepatitis B surface antigen, hepatitis C antibody
• Autoimmune hepatitis: ANA, SMA, anti-LKM antibodies, IgG levels (can mimic NAFLD) 4
• Drug-induced liver injury: Detailed medication/supplement history including over-the-counter products and herbal supplements
• Hemochromatosis: Iron studies, ferritin, transferrin saturation
• Wilson disease (if age <40): Ceruloplasmin, 24-hour urinary copper 5
• Alpha-1 antitrypsin deficiency: Alpha-1 antitrypsin level and phenotype
• Alcohol use: Detailed alcohol history (AST:ALT ratio >2 suggests alcoholic liver disease) 1

The normal bilirubin is reassuring as it suggests preserved hepatic synthetic function and makes acute liver failure or advanced cirrhosis less likely 2.

The Alkaline Phosphatase Elevation Matters

The ALP elevation to 270 U/L (~2-3x ULN) with normal bilirubin suggests a mixed hepatocellular-cholestatic pattern 1. While this can occur in NASH, consider:

• Confirm hepatic source: Check GGT (if elevated, confirms hepatobiliary origin) or fractionated ALP
• Rule out biliary pathology: While CT was reportedly normal, ultrasound is more sensitive for biliary tree evaluation 1
• Consider overlap syndromes: Rare cases may have features of both NASH and autoimmune hepatitis or primary biliary cholangitis 6, 4

Recommended Next Steps

Immediate actions:

1. Complete the diagnostic workup outlined above to exclude other treatable causes
2. Assess for metabolic risk factors: Diabetes, obesity, hypertension, dyslipidemia (present in 70-90% of NAFLD patients) 1
3. Consider liver biopsy if diagnosis remains uncertain or to stage disease severity, as imaging cannot distinguish simple steatosis from NASH or assess fibrosis 1
4. Assess for advanced fibrosis: Calculate FIB-4 or NAFLD Fibrosis Score; consider transient elastography 7, 8

The key point: These enzyme elevations indicate active liver injury requiring explanation. While NASH is the most likely diagnosis given the clinical context, the degree of elevation mandates excluding other superimposed or alternative diagnoses that may be treatable 1, 2.

Prognosis and Monitoring

If this proves to be NASH:

• Advancing fibrosis is the key predictor of liver-related morbidity and mortality 7
• Patients with advanced fibrosis (stage 3-4) are at increased risk for cirrhosis complications and hepatocellular carcinoma
• Normal ALT does not exclude advanced disease—in fact, ALT typically falls as fibrosis progresses 7, 9
• The presence of metabolic risk factors (diabetes, obesity) significantly increases risk of progressive disease 7, 8

Bottom line: Fatty liver disease can cause these enzyme elevations, but only when it has progressed to NASH with active inflammation. The CT finding of steatosis alone is insufficient to explain or characterize the severity of your liver injury—further diagnostic evaluation is mandatory.